Intellia Therapeutics Inc

Moderna's stock surged 176.9% to $174.38 on August 19, 2026, lifting its market capitalization to roughly $69.6 billion and strengthening its acquisition currency. The company still guides to a year-end 2026 cash and investments balance of between $4.7 billion and $5.2 billion, plus an undrawn $0.9 billion credit facility, and the $950 million Arbutus/Genevant settlement is largely resolved. CEO Stéphane Bancel said Moderna is preparing for "the growth stage of a company coming ahead of us," though management has not signaled M&A intent. Potential targets include Immatics, with a $1.3 billion market cap and an existing collaboration; Arbutus Biopharma, at $957.6 million, whose acquisition would extinguish $1.3 billion in contingent LNP patent exposure; Intellia Therapeutics, at $1.9 billion, with Phase 3 lonvo-z showing an 87% reduction in hereditary angioedema attacks; and Editas Medicine, at $442.3 million, offering cardiometabolic pipeline access.

Intellia Therapeutics reported positive top-line results from the Phase III HALO trial for LONVOSI in hereditary angioedema, achieving an 87% reduction in mean monthly attacks versus placebo and hitting all key secondary endpoints. The company is advancing a rolling BLA submission with the FDA and expects to announce acceptance by the end of 2026, positioning for a potential U.S. launch in the first half of 2027 as the world's first in vivo gene editing product. Cash, equivalents, and marketable securities totaled $628.4 million as of June 30, 2026, up from $605.1 million at the end of 2025, with the runway expected to fund operations at least into 2028 excluding potential product revenues. Collaboration revenue fell to $7.7 million from $14.2 million a year earlier, while R&D expenses declined to $82.6 million from $97.0 million, and G&A expenses rose to $37.8 million from $27.2 million, resulting in a net loss of $106.6 million compared to $101.3 million in the prior-year quarter. Intellia also resumed enrollment in both Phase III trials for NEXI in ATTR after resolving clinical holds, and identified a specific HLA allele associated with higher-grade transaminase elevations, enabling new patient-screening strategies.

A newly discovered CRISPR-based tool that destroys diseased cells by shredding their DNA is generating excitement in scientific circles, with potential long-term implications for gene-editing companies like CRISPR Therapeutics, Intellia Therapeutics, and Beam Therapeutics. Unlike traditional gene editing, this programmable cell-killing approach reads a signal unique to a diseased cell and cuts its DNA into fragments faster than the cell can repair, leading to cell death while sparing healthy cells. A May paper in Nature showed the therapy cutting lung cancer cell growth by about 50% in a lab dish, matching the chemotherapy drug cisplatin, and a June Nature paper extended the approach to target a gene mutated in 40% to 50% of all cancers. None of the major public CRISPR companies currently have this technology in their pipelines, though private German biotech Akribion Therapeutics is developing a program targeting HPV-positive head and neck cancer. The new papers significantly expand the addressable market for CRISPR-based medicine, and the incumbents may have an advantage due to their existing drug-delivery infrastructure.

Wall Street analysts expect Intellia Therapeutics to rise another 70% over the next 12 months, reaching more than $26, after the biotech reported positive phase 3 results for its CRISPR gene editing treatment lonvo-z. The one-time therapy for hereditary angioedema cut attacks by 87% versus placebo in a six-week trial, with 62% of patients remaining completely attack-free. Intellia has launched a rolling submission to the FDA and aims to complete it in the second half of this year, potentially launching the product in the first half of next year. The stock has already climbed more than 70% so far this year but remains well below its peak of over $150 a few years ago. The company also has a second late-stage candidate for transthyretin amyloidosis, and the positive data validate its broader gene editing platform.